摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-{6-[3-benzyl-8-(trifluoromethyl)quinolin-4-yloxy]hexyl}-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-methylimidazolidine-2,4-dione | 1192757-71-3

中文名称
——
中文别名
——
英文名称
3-{6-[3-benzyl-8-(trifluoromethyl)quinolin-4-yloxy]hexyl}-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-methylimidazolidine-2,4-dione
英文别名
3-[6-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]oxyhexyl]-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methylimidazolidine-2,4-dione
3-{6-[3-benzyl-8-(trifluoromethyl)quinolin-4-yloxy]hexyl}-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-methylimidazolidine-2,4-dione化学式
CAS
1192757-71-3
化学式
C35H34F3N3O5
mdl
——
分子量
633.667
InChiKey
PEIUOKHXDFEALE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    46
  • 可旋转键数:
    11
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.34
  • 拓扑面积:
    90
  • 氢给体数:
    1
  • 氢受体数:
    9

文献信息

  • QUINOLINE COMPOUNDS
    申请人:KOURA Minoru
    公开号:US20100016327A1
    公开(公告)日:2010-01-21
    [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.
    提供一种新型的LXRβ激动剂,可用作预防和/或治疗动脉粥样硬化;动脉硬化,如糖尿病引起的动脉硬化;血脂异常;高胆固醇血症;与脂质相关的疾病;由炎症性细胞因子引起的炎症性疾病;过敏性皮肤病;糖尿病;或阿尔茨海默病的治疗剂。通过以下一般式(1)表示的喹啉化合物或其盐,或它们的溶剂化合物。
  • QUINOLINE COMPOUND
    申请人:Kowa Company, Ltd.
    公开号:EP2272843A1
    公开(公告)日:2011-01-12
    It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is related to a quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.
    本发明旨在提供一种新型 LXRβ 激动剂,可作为动脉粥样硬化、动脉硬化(如糖尿病引起的动脉硬化)、血脂异常、高胆固醇血症、血脂相关疾病、由炎性细胞因子引起的炎症性疾病、皮肤病(如过敏性皮肤病)、糖尿病或阿尔茨海默病的预防和/或治疗药物。它与由以下通式(1)代表的喹啉化合物或其盐或它们的溶解物有关。
  • US8008306B2
    申请人:——
    公开号:US8008306B2
    公开(公告)日:2011-08-30
查看更多